<DOC>
	<DOCNO>NCT02292225</DOCNO>
	<brief_summary>To evaluate safety , pharmacokinetics , pharmacodynamics Duvelisib ( IPI-145 ) combination obinutuzumab patient Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma previously treat BTKi .</brief_summary>
	<brief_title>Duvelisib With Obinutuzumab Patients With CLL/SLL Previously Treated With BTKi ( SYNCHRONY )</brief_title>
	<detailed_description>This Phase 1b , open-label , dose escalation , safety tolerability study Duvelisib ( IPI-145 ) combination obinutuzumab subject Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma previously treat BTKi therapy .</detailed_description>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<criteria>≥18 year age Diagnosis Chronic lymphocytic leukemia Small lymphocytic lymphoma meet least one International Workshop Chronic Lymphocytic Leukemia ( IWCLL ) 2008 criterion treatment ( Binet Stage ≥ B and/or Rai Stage ≥ I symptoms ) Measurable disease lymph node tumor mass &gt; 1.5 cm least one dimension assess compute tomography ( CT ) Previous exposure BTKi therapy meet least one criterion : Progressive disease receive BTKi therapy , stable disease best response 12 month receive BTKi therapy Discontinued BTKi therapy due BTKi treatmentrelated intolerance Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 ( corresponds Karnofsky Performance Status [ KPS ] ≥60 % ) Subjects must able receive outpatient treatment laboratory monitoring ( specifically indicate ) institution administers study drug entire treatment period Richter 's transformation prolymphocytic leukemia Refractory obinutuzumab ( define progression relapse &lt; 12 month receive obinutuzumab monotherapy &lt; 24 month receive obinutuzumabcontaining regimen ) Progressive disease previously receive PI3K inhibitor ( e.g . GS1101 [ idelalisib ] , duvelisib ) serious/severe AE relate PI3K inhibitor treatment History severe reaction prior monoclonal antibody therapy ( define Grade 4 event and/or require permanent discontinuation ) Human immunodeficiency virus ( HIV ) Human T Cell Lymphotropic Virus 1 ( HTLV1 ) infection Prior , current , chronic hepatitis B hepatitis C infection History tuberculosis treatment within precede 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Phase 1b , CLL/SLL , PI3K</keyword>
</DOC>